FDA Approves ALECENSA® as Adjuvant Treatment for ALK-Positive Non Small Cell Lung Cancer
FDA Approves ENHERTU® for Unresectable or Metastatic HER2-Positive Solid Tumors
Novel Prognostic Factors for Treatment-Free Remission in Chronic Myeloid leukemia
FDA Approves RYBREVANT® in Combination with Chemotherapy for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
TUKYSA® Plus KADCYLA® in Advanced HER2-Positive Breast Cancer
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
FDA Approves AUGTYRO® for ROS1-positive Non-Small Cell Lung Cancer
Biomarker Driven ELAHERE® in FR alpha-Positive, Platinum-Resistant Ovarian Cancer
FDA Approves TRUQAP® with Fulvestrant for Advanced Breast Cancer
Osimertinib Plus Chemotherapy Superior to Osimertinib Alone in Advanced EGFR Mutated Non Small Cell Lung Cancer
Amivantamab plus Chemotherapy with and without Lazertinib after Progression on Osimertinib in Advanced Lung Cancer
FDA Approves Ivosidenib for Myelodysplastic Syndromes
Single Blood Test for Multi-Cancer Early Detection
KEYTRUDA® in Combination with HER2 Blockade Improves PFS in Gastric and GE Junction Cancer
Zolbetuximab plus CAPOX in Biomarker Positive Advanced Gastric or GEJ Cancer
Osimertinib Plus Chemotherapy Superior to Osimertinib Alone in Advanced EGFR Mutated Non Small Cell Lung Cancer
Germline Testing to Identify 11 Genes Linked to Aggressive Prostate Cancer
FDA Approves Pralsetinib for Non Small Cell Lung Cancer with RET gene fusions
FDA Approves AKEEGA® for Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
Targeting ESR1 Mutations in Estrogen-Positive Advanced Breast Cancer